: 24

Colloid milium
Colloid milium is a skin condition characterized by a translucent, flesh-colored, or slightly yellow, 1 to 5 mm papules. : 31

Pathophysiology
Miliaria occurs when the sweat gland ducts get clogged due to dead skin cells or bacteria such as Staphylococcus epidermidis, a common bacterium that occurs on the skin, which is also associated with acne. The trapped sweat leads to irritation (prickling), itching, and a rash of very small blisters, usually in a localized area of the skin. Prevention
Prickly heat can be prevented by avoiding activities that induce sweating, using air conditioning to cool the environment, wearing light clothing, and in general, avoiding hot and humid weather. Frequent cool showers or cool baths with mild soap can help to prevent heat rash. Treatment
The primary remedy for prickly heat or rash is to wear lighter clothing, or otherwise avoid overheating ones body. The immediate treatment of the involved skin areas involves the use of a soothing ointment such as calamine lotion. Talcum powder may be used in some cases. Medical assistance should be sought for the first episode of a rash with the appearance of miliaria. The differential diagnosis includes several conditions that an experienced practitioner should be able to recognise and may require treatment distinct from the usual measures taken for miliaria. In most cases, the rash of miliaria resolves without intervention, but  severe cases can last for weeks and cause significant disability.
As with the Sterne (veterinary) anthrax vaccine strain and the similar British anthrax vaccine (known as AVP), AVA lacks the capsule plasmid pXO2 (required for full virulence) and is composed chiefly of the anthrax protective antigen (PA) with small amounts of edema factor (EF) and lethal factor (LF) that may vary from lot to lot. Other uncharacterized bacterial byproducts are also present. Whether or not the EF and LF contribute to the vaccines efficacy is not known. AVA has smaller amounts of EF and LF than AVP. Adjuvant
AVA contains aluminium hydroxide (alhydrogel) to adsorb PA as well as to serve as an adjuvant (immune enhancer). As such it is believed to stimulate humoral, but not cell-mediated, immunity. Each dose of the vaccine contains no more than 0.83 mg aluminum per 0.5 mL dose. (This is near the allowed upper limit of 0.85 mg/dose.) It also contains 0.0025% benzethonium chloride as a preservative and 0.0037% formaldehyde as a stabilizer. The mechanism of action of the adjuvant is not entirely understood. Potency/immunogenicity
Vaccination of humans with AVA induces an immune response to PA. More than 1/3 of subjects develop detectable anti-PA IgG after a single inoculation; 95% do so after a 2nd injection; and 100% after 3 doses. The peak IgG response occurs after the 4th (6 month) dose. The potency of AVA vaccine lots is routinely determined both by the survival rates of parenterally challenged guinea pigs and their anti-PA antibody titres as measured by an enzyme linked immunosorbant assay (ELISA).